Can COMPASS Bring Psilocybin’s ‘Magic’ To Depression?
COMPASS Pathways Hopes To Market its Psilocybin Capsule By 2025
COMPASS is testing a synthetic form of psilocybin, the active “magic mushroom” ingredient, in long-term depression patients, and thinks the capsule can be approved by 2025, its co-founder tells Scrip.
